Sharif joined Polaris in 2019 and is a senior associate in the firm’s San Francisco office, where he invests across biotech and healthcare services sectors. Sharif is also a practicing physician who sees patients at Stanford, where he completed his Internal Medicine residency.
Prior to joining Polaris, Sharif worked in Business Development for RNA therapeutics company Translate Bio and in healthcare investing for SR One, where he supported cell therapy portfolio companies NKarta and Arcellx in Corporate Strategy roles.
Sharif is also the cofounder of USMLE Pro, a medical education company, and has published prolifically in clinical research and healthcare delivery. Sharif holds an MD from the Johns Hopkins School of Medicine, an MBA from Harvard Business School, and an MS and BS in Biology from Yale University.
The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.